<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634436</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1209-101</org_study_id>
    <nct_id>NCT03634436</nct_id>
  </id_info>
  <brief_title>The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects</brief_title>
  <official_title>Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Study Following A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Single Center, Randomized, Double-blind, Dose Escalation, Placebo Parallel
      Controlled PhaseⅠClinical study to Evaluate the Safety, Tolerability and Pharmacokinetics,
      Pharmacodynamics with A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects.

      The primary objective of this study is to investigate the safety and tolerability of a range
      of subcutaneous SHR-1209 in healthy subjects. Secondary objectives are to determine the
      pharmacokinetics (PK) and pharmacodynamics(PD) profile of SHR-1209 in healthy subjects
      including assessment of immunogenicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      32 adult healthy subjects with 4 dose groups will be enrolled in the study, including two
      subjects in the lowest dose group, all of whom received the SHR-1209 without placebo control.
      The other three groups have 10 subjects in each group, 8 administered SHR-1209 and 2
      administered placebo. The primary endpoint is the Safety and Tolerability : adverse events,
      vital signs, physical examination, laboratory examination, 12 lead electrocardiogram,
      injection site reactions, etc.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Pre-dose to 150 days after dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-time to maximum concentration (Tmax)</measure>
    <time_frame>Pre-dose to 150 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-maximum concentration (Cmax)</measure>
    <time_frame>Pre-dose to 150 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-area under curve (AUC)</measure>
    <time_frame>Pre-dose to 150 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in Low-Density Lipoprotein Cholesterol (LDL-C) from baseline</measure>
    <time_frame>Pre-dose to 150 days after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter-change in Total Cholesterol (T-C) from baseline</measure>
    <time_frame>Pre-dose to 150 days after dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hypercholesteremia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1209 dose 1 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1209 dose 2 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1209 dose 3 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1209 dose 4 versus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1209</intervention_name>
    <description>Pharmaceutical form: lyophilized formulation
Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: lyophilized formulation
Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 and ≤45 years old;

          2. The body mass index (BMI) should be 19 or greater and &lt; 28kg/m2, the male weigh
             ≥50.0kg and &lt;90.0kg, and the female weigh ≥45.0kg and &lt;90.0kg;

          3. Serum LDL-C concentration≥2.0mmol/L and &lt; 4.1mmol/L;

          4. Fasting triglycerides &lt; 2.3 mmol/L;

          5. The comprehensive physical examination is eligible or slightly abnormal but the
             researchers determine no clinical implication.

          6. Signed informed consent.

        Exclusion Criteria:

          1. Subjects determined by the researchers have diseases that affect drug absorption,
             distribution, metabolism and excretion or low compliance;

          2. A clinical history of drug allergy or a history of atopic allergic diseases (asthma,
             urticaria, eczema dermatitis) or a known allergy to experimental or similar
             experimental drugs;

          3. Serum creatinine exceeded the upper limit of normal value (ULN) during screening;

          4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma pancreatic
             acyl transferase (GGT), more than 2 x ULN, or total bilirubin more than 1.5 x ULN
             during screening;

          5. Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination,
             hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were
             positive;

          6. Subjects with previous malignant tumor diseases;

          7. 3 months prior to screening involved in any drug or medical device clinical subjects,
             or within 5 half-life of drugs (test drug half-life more than 3 months) before
             screening. etc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jing Xia</last_name>
    <phone>+86-18910446100</phone>
    <email>xiajing@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Zhu</last_name>
    <phone>+86-13380043088</phone>
    <email>zhubo@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FuWai Hospital , Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li xin Jiang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR-1209 Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

